Pharma steps up as coronavirus cases soar to 400,000-plusWith the coronavirus pandemic gathering momentum outside China, AstraZeneca has said it will donate 9 million face masks Share XPharma steps up as coronavirus cases soar to 400,000-plushttps://pharmaphorum.com/news/pharma-steps-up-as-coronavirus-cases-soar-to-400000-plus/
Merck’s chronic cough drug gefapixant clears phase 3 testMerck & Co/MSD’s experimental drug gefapixant has improved the frequency of coughing in a pair of phase 3 Share XMerck’s chronic cough drug gefapixant clears phase 3 testhttps://pharmaphorum.com/news/mercks-chronic-cough-drug-gefapixant-clears-phase-3-test/
WebMD buys employee wellbeing platform StayWell from MerckHealth information firm WebMD has bought The StayWell Company, a subsidiary of US-based Merck & Co. Based in Yardley, Share XWebMD buys employee wellbeing platform StayWell from Merckhttps://pharmaphorum.com/news/webmd-buys-employee-wellbeing-platform-staywell-from-merck/
AZ’s cediranib falls short again in ovarian cancer combinationAstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it Share XAZ’s cediranib falls short again in ovarian cancer combinationhttps://pharmaphorum.com/news/azs-cediranib-falls-short-again-in-ovarian-cancer-combination/
Merck’s digital chief Scholefield jumps ship to MarriottMerck & Co’s chief information and digital officer Jim Scholefield is leaving the company to take a similar Share XMerck’s digital chief Scholefield jumps ship to Marriotthttps://pharmaphorum.com/news/mercks-digital-chief-scholefield-jumps-ship-to-marriott/
BMS builds case for long-term use of Opdivo in kidney cancerBristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, Share XBMS builds case for long-term use of Opdivo in kidney cancerhttps://pharmaphorum.com/news/bms-builds-case-for-long-term-use-of-opdivo-in-kidney-cancer/
Merck & Co spin off could start a trend in big pharmaMerck & Co’s strategy to spin off its older drugs and biosimilars into a new stand-alone business will Share XMerck & Co spin off could start a trend in big pharmahttps://pharmaphorum.com/news/merck-cos-spin-off-closely-watched-by/
Merck to spin old drugs into ‘NewCo’ focused on generics, women’s healthMerck & Co has followed the lead of other big pharma groups like Pfizer and GlaxoSmithKline by hiving Share XMerck to spin old drugs into ‘NewCo’ focused on generics, women’s healthhttps://pharmaphorum.com/news/merck-to-spin-old-drugs-into-newco-focused-on-generics-womens-health/
FDA sets June date for latest review of Merck’s last-ditch antibioticThe FDA has started a six-month priority review of Merck & Co/MSD’s triple antibiotic Recarbrio in a new Share XFDA sets June date for latest review of Merck’s last-ditch antibiotichttps://pharmaphorum.com/news/fda-sets-june-date-for-latest-review-of-mercks-last-ditch-antibiotic/
